Eli Lilly (LLY) Q4 2025 earnings review
The Trillion-Dollar Weight Loss Engine Is Just Warming Up
Eli Lilly delivered a knockout Q4, proving that the demand for incretins is nowhere near a ceiling. Revenue surged 43% to $19.3B, driven by a staggering 46% increase in volume that easily overpowered a 5% drag from lower realized prices. Mounjaro and Zepbound combined for over $11.6B in the quarter alone. While the effective tax rate jumped to nearly 20%, impacting the bottom line slightly, the operational leverage is undeniable. The real story is the FY26 guidance: projecting $80-83B in revenue implies the company plans to add ~$16B in new sales next year—roughly the size of a Fortune 500 company.
🐂 Bull Case
Mounjaro ($7.4B) and Zepbound ($4.3B) grew 110% and 123% respectively. These two drugs now generate annualized run-rate revenue of over $46B, cementing Lilly's leadership in the metabolic space.
Innovation isn't slowing. Lilly submitted orforglipron (oral GLP-1) for obesity in the U.S. and Japan, and positive Phase 3 results for Retatrutide (triple agonist) in knee osteoarthritis suggest the next generation of weight loss drugs is on track.
🐻 Bear Case
Volume is masking pricing weakness. Realized prices fell 5% globally and 7% in the U.S. due to rebate dynamics and savings card utilization. As competition intensifies, net pricing could remain a headwind.
The effective tax rate spiked to 19.7% (up from 12.5% a year ago) due to tax law changes and jurisdictional mix. Guidance suggests this higher rate (18-19%) is the new normal, creating a permanent drag on EPS growth.
⚖️ Verdict: 🟢🟢
Strong Buy. Lilly is executing perfectly on the most significant pharmaceutical product cycle in history. Volume growth is overpowering pricing headwinds, and the pipeline ensures durability through the end of the decade.
Key Themes
The Mounjaro & Zepbound Juggernaut
The scale of the incretin ramp is historic. Mounjaro sales more than doubled to $7.4B, while Zepbound reached $4.26B in its second full year. Crucially, U.S. volume surged 50%, confirming that manufacturing capacity is finally catching up to demand. The 'shortage' narrative is shifting to a 'market expansion' narrative.
Realized Pricing Pressure
While top-line growth is stellar, the quality of revenue shows cracks. U.S. revenue grew 43% driven by 50% volume growth, but offset by a 7% decline in realized prices. This isn't just one quarter; it's a trend. As access expands to government payers and lower-tier commercial plans, gross-to-net spreads are widening.
Pipeline: The Next Wave is Here
Lilly is not resting on Mounjaro. The company highlighted submissions for orforglipron (oral GLP-1) in the U.S. and Japan, positioning them to tap into the needle-averse market. Furthermore, positive Phase 3 results for retatrutide (triple G agonist) in obesity with knee osteoarthritis validates the efficacy of their next-gen injectable.
Operational Leverage
Despite a massive ramp in R&D investment (+26%) and SG&A (+29%) to support launches, revenue growth (+43%) outpaced expenses significantly. This resulted in operating income growing 63% YoY to $8.4B. The margin story remains intact despite pricing headwinds.
Legacy Portfolio Drag
The focus is rightfully on new drugs, but legacy diabetes products are fading fast. Trulicity (not explicitly broken out in text but implied via 'Key Products' exclusion) and older insulins are likely facing steep declines, creating a hole that new products must fill before showing net growth. (Note: Trulicity data missing from Q4 text, but trend was -25% in prior year).
Other KPIs
Stable. Flat YoY (83.2% vs 83.2% in 24Q4). This is a victory given the negative pricing pressure (-5%). It indicates significant manufacturing efficiencies and a favorable mix shift toward higher-margin incretins are offsetting price erosion.
Accelerating. Up 41% YoY. Even with a significantly higher tax rate (19.7% vs 13.2%), the sheer volume of high-margin product sales drove massive bottom-line expansion.
Accelerating. Up 26% YoY. Lilly is reinvesting heavily (20% of revenue) into the pipeline, specifically late-stage trials for orforglipron and retatrutide, ensuring they don't face an 'innovation cliff' in the 2030s.
Guidance
Decelerating mathematically, but massive in absolute terms. The midpoint implies ~25% YoY growth off a massive $65.2B base. This suggests adding ~$16B in new revenue in a single year.
Accelerating. The midpoint ($34.25) implies ~41% growth over FY25's $24.21. This demonstrates strong earnings leverage as the manufacturing base stabilizes and scales.
Stable. Consistent with the elevated Q4 rate (19.7%), signaling that the days of ~13% effective tax rates are over. Investors must model this higher burden permanently.
Key Questions
Pricing vs. Access Trade-off
With realized prices down 7% in the U.S., are we approaching a floor, or should we expect double-digit price erosion as you negotiate broader Medicare/Medicaid access in 2026?
Oral GLP-1 Cannibalization
With Orforglipron submitted, how does management view the interplay with Zepbound? Is the oral option purely additive, or do you model significant switching from the injectable franchise?
Supply Chain Ceiling
The FY26 guidance implies selling ~$80B+ of product. Does the current manufacturing footprint support this volume, or is the top end of guidance constrained by supply rather than demand?